10-Q: DaVita Q3 Earnings Decline Amid Rising Costs, Cyber Incident

DaVita Inc. reported a significant drop in net income and diluted EPS for the third quarter and year-to-date periods, impacted by increased operating expenses, higher debt costs, and a cybersecurity incident.

Summary

• Total revenues increased by 4.8% to $3.42 billion for Q3 2025 compared to Q3 2024, and by 5.3% to $10.02 billion for the nine months ended September 30, 2025, compared to the same period in 2024.
• Net income attributable to DaVita Inc. decreased by 29.9% to $150.3 million for Q3 2025 and by 24.3% to $512.6 million for the nine months ended September 30, 2025.
• Diluted earnings per share fell by 18.4% to $2.04 for Q3 2025 and by 13.6% to $6.62 for the nine months ended September 30, 2025.
• Operating income decreased by 5.5% to $505.8 million for Q3 2025 and by 2.8% to $1.48 billion for the nine months ended September 30, 2025.
• Patient care costs per treatment in U.S. dialysis increased by 1.9% to $273.54 in Q3 2025 compared to Q2 2025, and by 6.0% to $271.23 for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company incurred $11.7 million in general and administrative charges related to a cybersecurity incident in Q3 2025, with total year-to-date charges of $25.2 million.
• Long-term debt increased by 10.9% to $10.18 billion as of September 30, 2025, from $9.18 billion at December 31, 2024.
• DaVita's total shareholders' equity shifted to a deficit of $(571.9) million as of September 30, 2025, from a positive $121.1 million at December 31, 2024.
• The company repurchased 10.0 million shares of common stock for $1.46 billion during the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: While revenues grew, profitability metrics (net income, EPS, operating income) significantly declined, and the company's equity moved into a deficit. This, combined with ongoing cybersecurity impacts, rising debt costs, and various legal/regulatory challenges, indicates a negative financial performance and outlook despite some operational improvements and share repurchases.

Positives

• Total revenues increased both for the quarter (4.8% to $3.42 billion) and year-to-date periods (5.3% to $10.02 billion).
• U.S. dialysis average patient service revenue per treatment increased by 1.5% in Q3 2025 compared to Q2 2025, and by 3.9% year-to-date, partly due to the incorporation of phosphate binders into the ESRD PPS bundle and Medicare rate increases.
• International operating income increased significantly by 82.4% for the nine months ended September 30, 2025, driven by non-acquired and acquired treatment growth.
• The company successfully refinanced its Term Loan B-1 with a new Term Loan B-2 facility and issued new senior notes, demonstrating access to capital markets.
• Share repurchase authorization was increased by $2.0 billion, indicating management's commitment to returning capital to shareholders.
• Improvements in certain labor-related costs such as training and productivity are noted, with expectations for reduced turnover.

Negatives

• Significant decline in net income attributable to DaVita Inc. by 29.9% for Q3 2025 and 24.3% year-to-date.
• Diluted EPS decreased by 18.4% for Q3 2025 and 13.6% year-to-date.
• Operating income decreased by 5.5% for Q3 2025 and 2.8% year-to-date.
• Patient care costs per treatment increased by 6.0% year-to-date, driven by pharmaceutical costs (phosphate binders) and compensation expenses.
• Debt expense increased by 30.1% for the nine months ended September 30, 2025, primarily due to higher weighted average effective interest rates and increased debt balance.
• Other loss, net, increased substantially by 145.8% for Q3 2025 and 43.5% year-to-date, largely due to increased equity investment losses at Mozarc Medical Holding LLC, including $25.9 million in impairment and restructuring charges.
• The company's total shareholders' equity moved into a deficit of $(571.9) million as of September 30, 2025, from a positive $121.1 million at December 31, 2024.
• The cybersecurity incident in April 2025 resulted in $25.2 million in year-to-date charges and adversely impacted billing, revenue collection, and patient census.
• U.S. dialysis treatments decreased by 1.4% year-to-date, primarily due to higher mortality, missed treatments from a severe flu season, and fewer treatment days.
• Integrated Kidney Care (IKC) operating income shifted to a loss of $(21) million in Q3 2025 from a gain of $26 million in Q2 2025, primarily due to decreased shared savings and special needs plan revenues.

Risks

• External conditions, including general economic, marketplace, and global health conditions, such as inflation, interest rate volatility, and geopolitical uncertainty, could materially impact the business.
• Future risks and uncertainties from the April 2025 cybersecurity incident, including impacted data, litigation, reputational harm, and regulatory actions, could adversely affect the business.
• A prolonged U.S. federal government shutdown could delay Medicare enrollment, licensing, and claims resolution, adversely impacting the business.
• Failure to extend enhanced premium tax credits for ACA health insurance exchanges could reduce commercial health insurance enrollment, negatively impacting revenue.
• Elevated teammate turnover or labor costs, including wage pressures and increased union organizing activities, could continue to impact expenses.
• Increased competition from dialysis providers and new entrants, along with innovative technologies or treatments, could erode the patient base and impact reimbursement rates.
• Continued downward pressure on average realized payment rates from higher-paying commercial payor plans and potential reductions in government payment rates (Medicare, Medicaid) pose risks.
• Reliance on significant suppliers and third-party vendors for critical clinical supplies and equipment, with risks of closure, reduction, or disruption of services.
• Compliance with complex and evolving government regulations, including antitrust matters, and ongoing legal proceedings could result in substantial financial penalties, harm to reputation, or changes in business practices.
• Variability of cash flows, including extended billing or collections cycles due to system defects or cybersecurity incidents, could impact the ability to service indebtedness or fund liquidity needs.
• Risks associated with successfully implementing Integrated Kidney Care (IKC) and Value-Based Care (VBC) initiatives in a complex and highly regulated environment.
• Goodwill, a significant asset at $7.54 billion, is subject to future impairment risk, although no impairment was indicated as of September 30, 2025.

Future Outlook

The company expects continued impact from global economic conditions, inflationary pressures, and U.S. administration policies on expenses, particularly staffing and labor costs. While improvements in labor-related costs are anticipated due to reduced turnover, union organizing activities persist. A prolonged federal government shutdown could delay Medicare enrollment and claims, and the potential expiration of enhanced ACA premium tax credits may reduce commercial health insurance enrollment. The full financial impact of the cybersecurity incident remains uncertain, including insurance coverage. CMS estimates a 1.9% increase in ESRD freestanding facilities average reimbursement for 2026. The company plans to add additional service offerings and pursue strategic initiatives, including healthcare services not related to kidney disease.

Management Comments

• "We have seen improvements in certain labor related costs such as training and productivity, and we expect to continue to see improvements in labor-related costs due to, among other things, reduced turnover."
• "We believe that the aforementioned developments and general economic, marketplace and global health conditions will continue to impact the Company in the future. Their ultimate impact depends on future developments that are highly uncertain and difficult to predict."
• "At this time we are unable to predict the extent of these and other potential liabilities or consequences that may arise from this incident [cybersecurity]."
• "We do not yet know the full impact of the cybersecurity incident, including how much of the financial impact will be covered by insurance."

Industry Context

The dialysis industry continues to face challenges from external conditions such as inflation, interest rate volatility, and labor market pressures, leading to increased operating expenses. Regulatory changes, like the incorporation of phosphate binders into the ESRD PPS bundle, impact revenue and costs. The industry is also navigating the evolving landscape of integrated kidney care and value-based care models, with companies like DaVita expanding into these areas. The potential for government shutdowns and changes in healthcare policy, such as the expiration of ACA premium tax credits, introduce significant uncertainty regarding patient insurance mix and reimbursement. Increased competition and the emergence of new technologies or treatments are ongoing trends.

Comparison to Industry Standards

• The acquisition of dialysis operations from Fresenius Medical Care AG in Brazil indicates Fresenius as a direct competitor in the international dialysis market, though no specific comparable financial results or projects are detailed in the filing for direct comparison.
• The discussion of union organizing activities in California clinics suggests labor relations challenges that may be specific to DaVita or broader within the healthcare services industry, but no specific comparable companies or industry benchmarks are provided.
• The company's integrated kidney care (IKC) and value-based care (VBC) initiatives are part of a broader industry trend towards more holistic and outcome-based care models, but no specific comparable projects or results from other companies are detailed.

Legal Proceedings

• **2020 U.S. Attorney New Jersey Investigation**: The U.S. District Court for the District of New Jersey dismissed U.S. ex rel. Doe v. DaVita Inc. without prejudice on April 13, 2022. In a related matter, the U.S. District Court, Eastern District of Pennsylvania, unsealed an amended complaint in U.S. ex rel. Bayne v. DaVita Inc., et al. on October 14, 2022. The company's motion to dismiss the fourth amended complaint was denied on April 29, 2025, and the company answered the complaint on July 21, 2025, intending to defend the action.
• **2020 California Department of Insurance Investigation**: An ongoing investigation with subpoenas requesting information on patient communications about insurance plans, financial assistance from the American Kidney Fund (AKF), and donations to AKF. The company is cooperating.
• **2023 District of Columbia Office of Attorney General Investigation**: An antitrust investigation into the AKF, with a Civil Investigative Demand issued in January 2023 requesting information on communications with AKF, donations, and patient/provider/insurer communications regarding AKF. The company is cooperating.
• **2024 Federal Trade Commission Investigation**: Two Civil Investigative Demands received in April 2024 for an industry antitrust investigation under Section 5 of the Federal Trade Commission Act, focusing on medical director services and dialysis services, particularly restrictive covenants with physicians. The company is cooperating.
• **2021 Antitrust Indictment and Putative Class Action Suit**: Following an acquittal in a federal antitrust criminal case on April 15, 2022, the company and its former CEO were added as defendants in a consolidated putative class action complaint (In re Outpatient Medical Center Employee Antitrust Litigation) alleging Sherman Act violations. A third amended complaint was filed on October 27, 2024, and a motion to certify the class was filed on September 15, 2025. The company disputes the allegations and intends to defend.

Related Party Transactions

• The company had a share repurchase obligation with Berkshire Hathaway Inc. for $54,347 thousand as of September 30, 2025, which was settled on October 27, 2025, for 402 shares of common stock.

Stakeholder Impact

• **Shareholders**: Negative impact from significant declines in net income and EPS, and the shift to a shareholders' equity deficit. Positive impact from ongoing share repurchase program.
• **Patients**: Negative impact from higher mortality and missed treatments due to a severe flu season, and potential disruptions from the cybersecurity incident. Potential delays in Medicare enrollment and claims due to government shutdown.
• **Employees**: Increased compensation expenses and wage rates, but also improvements in training and productivity. Potential for increased union organizing activities.
• **Customers/Payors**: Changes in reimbursement rates (e.g., phosphate binders, CMS proposed rule) and potential shifts in commercial insurance enrollment due to policy changes.
• **Creditors**: Increased long-term debt and higher debt expense, but the company believes it has sufficient liquidity to fund debt service.

Next Steps

• Continue to defend against the U.S. ex rel. Bayne v. DaVita Inc., et al. lawsuit, with the company having answered the complaint on July 21, 2025.
• Defend against the motion to certify the class in the In re Outpatient Medical Center Employee Antitrust Litigation, filed on September 15, 2025.
• Cooperate with the California Department of Insurance, District of Columbia Office of Attorney General, and Federal Trade Commission investigations.
• Monitor and respond to potential impacts of the U.S. federal government shutdown and the expiration of enhanced premium tax credits for ACA health insurance.
• Assess the full impact of the cybersecurity incident, including potential liabilities, litigation, and insurance coverage.
• Implement new technologies or treatments in the business.
• Identify and implement cost-saving opportunities.
• Continue to expand operations and services in markets outside the United States and potentially into healthcare services not related to kidney disease.
• The company expects to recognize $156,908 thousand in unrecognized stock-based compensation expense over a weighted average remaining period of 1.3 years.
• The company has $2,432,597 thousand available under current authorizations for additional share repurchases as of October 28, 2025.
• The company's income tax footnote for the fiscal year ended December 31, 2025, will reflect expanded disclosure requirements from ASU 2023-09.
• The company is assessing the effect of ASU 2024-03 (effective for fiscal years beginning after December 15, 2026) and ASU 2025-06 (effective for fiscal years beginning after December 15, 2027) on its consolidated financial statements.

Key Dates

Recommendation

The significant decline in net income and diluted EPS, coupled with the company's shareholders' equity moving into a deficit, signals a deteriorating financial position. While revenue growth is present, it is overshadowed by rising operating costs, increased debt expense, and substantial equity investment losses. The ongoing impacts of the cybersecurity incident, a challenging labor market, and a complex regulatory and legal environment present considerable headwinds. Despite share repurchases, the overall financial health and profitability trends suggest a negative outlook for investors.

Keywords

Dialysis, Kidney Care, Healthcare Services, SEC Filing, 10-Q, Financial Results, Cybersecurity, Debt Refinancing, Share Repurchase, Medicare, Medicaid, ESRD, ESKD, Integrated Kidney Care, Value-Based Care, Patient Services, Operating Income, Net Income, EPS, Long-term Debt, Acquisitions, Fresenius Medical Care, Mozarc Medical, Labor Costs, Government Regulation, Antitrust, Litigation